Skip Ribbon Commands
Skip to main content
Prof Hausenloy Derek

Prof Hausenloy Derek

​PhD, MBChB (Honours), BSc

Senior Consultant

National Heart Centre Singapore

Specialty: Cardiology

Sub-specialties: Cardiac Magnetic Resonance Imaging

Clinical Appointments

  • Director of National Heart Research Institute Singapore (NHRIS) National Heart Centre SingaporeNational Heart Centre Singapore
  • Senior Consultant Department of Cardiology National Heart Centre SingaporeNational Heart Centre Singapore

Academic Appointments

  • Academic Vice Chair, Research SingHealth Duke-NUS Cardiovascular Sciences Academic Clinical Programme


Derek Hausenloy is Professor in the Cardiovascular & Metabolic Disorders Signature Program, Duke-National University of Singapore Medical School, and Director of National Heart Research Institute Singapore (NHRIS) and Senior Consultant from Department of Cardiology at the National Heart Centre Singapore (NHCS). He is also Professor in the Institute of Cardiovascular Sciences, University College London.

He conducts basic, translational and clinical research in the areas of ischaemic heart disease, heart failure, cardioprotection, and cardiac MRI. His main research focus is on discovering novel therapies for protecting the heart against acute ischaemia/reperfusion injury and heart failure. His research ranges from cellular and animal disease models of cardiovascular disease to proof-of-concept clinical studies in acute myocardial infarction, heart failure and cardiac bypass surgery patients, and finally to large multi-centre randomised clinical trials focused on clinical outcomes. He also uses human iPSC-derived cardiomyocytes to model cardiomyopathies in order to elucidate underlying mechanisms and identify novel therapeutic targets and has an interest in discovering new treatment targets for peripheral arterial disease.

 He has been the Private Investigator (PI) on over 40 research grants (totalling $30M), and has authored 332 papers (with 38,448 citations), and his H-index is 96. In 2018, 2020 and 2021 he was named Highly Cited Researcher by Clarivate Analytics (awarded to top 1% of researchers worldwide).


  • PhD, University College London, UK, 2004
  • MBChB (Honours), University of Manchester, 1996
  • BSc Biomedical Sciences (First Class Honours), 1993

Professional Appointments and Committee Memberships

  • ​Director of National Heart Research Institute Singapore (NHRIS)
  • Academic Vice Chair, Research, SingHealth Duke-NUS Cardiovascular Sciences Academic Clinical Programme, May 2021 to Present
  • Heart Protection Theme Lead, National Heart Research Institute Singapore
  • Professor, Programme in Cardiovascular & Metabolic Disorders, Duke-NUS Medical School  
  • Senior Consultant, Department of Cardiology, National Heart Centre Singapore
  • Professor of Cardiovascular Medicine, University College London, UK 
  • Chair of EU-CARDIOPROTECTION CA16225 COST Action, October 2017 to Present
  • Member of the ESC Council on Basic Cardiovascular Science, September 2012 to Present
  • Fellow of the Royal College of Physicians (FRCP), October 2011 to Present
  • Fellow of the European Society of Cardiology (FESC), May 2009 to Present
  • Fellow of the American College of Cardiology (FACC), February 2009 to Present


  • NMRC STaR Investigator Award, December 2021
  • Dean's Excellence Award in Research 2019, Duke-NUS, Singapore, February 2020
  • Highly Cited Researcher 2018 (awarded to top 1% of researchers), November 2018, 2020, 2021
  • Doctor Honoris Causa, Semmelweis University, Budapest, Hungary, November 2019
  • Fellow of the International Society of Heart Research (FISHR), September 2018
  • European Society of Cardiology (ESC) Outstanding Achievement Award, July 2013
  • Winner of the BSCR Marshall Research Excellence Award, July 2012
  • Fellow of the Royal College of Physicians (FRCP), October 2011
  • Fellow of the European Society of Cardiology (FESC), May 2009
  • Fellow of the American College of Cardiology (FACC), February 2009
  • Winner of the Novartis Bursary, Novartis Mitochondrial Symposium, London, UK, November 2006
  • Finalist in Young Investigator Award, ISHR European Section meeting, Manchester, UK, June 2006
  • Winner of Young Investigator Award, British Cardiac Society, Glasgow, UK, May 2006
  • Winner of ISHR-Servier Research Fellowship, April 2006

Research Interests

  • Discovering new treatments for protecting the heart from acute myocardial infarction and heart failure
  • Human induced pluripotential stem cell-derived cardiomyocytes for modelling cardiac diseases
  • Nanocarriers to deliver therapeutics to the heart
  • Cardiac MRI in acute myocardial infarction and heart failure
  • Discovering new treatments for peripheral arterial disease


  • ​Bulluck H, Paradies V, Barbato E, Baumbach A, Bøtker HE, Capodanno D, De Caterina R, Cavallini C, Davidson SM, Feldman DN, Ferdinandy P, Gili S, Gyöngyösi M, Kunadian V, Ooi SY, Madonna R, Marber M, Mehran R, Ndrepepa G, Perrino C, Schüpke S, Silvain J, Sluijter JPG, Tarantini G, Toth GG, Van Laake LW, von Birgelen C, Zeitouni M, Jaffe AS, Thygesen K, Hausenloy DJ. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2021 Jul 15;42(27):2630-2642. doi: 10.1093/eurheartj/ehab271. IF 29.983
  • Silvain J, Zeitouni M, Paradies V, Zheng HL, Ndrepepa G, Cavallini C, Feldman DN, Sharma SK, Mehilli J, Gili S, Barbato E, Tarantini G, Ooi SY, von Birgelen C, Jaffe AS, Thygesen K, Montalescot G, Bulluck H, Hausenloy DJ. Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patient-level data.
    Eur Heart J. 2021 Jan 21;42(4):323-334. doi: 10.1093/eurheartj/ehaa885. PMID: 33257958 Nov 30:ehaa885. IF 29.983.
  • Hausenloy DJ, Kharbanda RK, Møller UK, Ramlall M, Aarøe J, Butler R, Bulluck H, Clayton T, Dana A, Dodd M, Engstrom T, Evans R, Lassen JF, Christensen EF, Garcia-Ruiz JM, Gorog DA, Hjort J, Houghton RF, Ibanez B, Knight R, Lippert FK, Lønborg JT, Maeng M, Milasinovic D, More R, Nicholas JM, Jensen LO, Perkins A, Radovanovic N, Rakhit RD, Ravkilde J, Ryding AD, Schmidt MR, Riddervold IS, Sørensen HT, Stankovic G, Varma M, Webb I, Terkelsen CJ, Greenwood JP, Yellon DM, Bøtker HE; CONDI-2/ERIC-PPCI Investigators. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
    Lancet. 2019 Oct 19;394(10207):1415-1424. doi: 10.1016/S0140-6736(19)32039-2. IF 60.392.
  • Nagel, E, Greenwood J, McCann GP, Shah AJ, Hussain ST, Plein S, Bucciarelli-Ducci C, Paul M, Westwood MA, Marber M, Richter WS, Puntmann VO, Shwenke C, Schulz-Menger J, Das R,  Hausenloy DJ, Steen H, Berry C.
    Comparative Effectiveness of Magnetic Resonance Perfusion and Fractional Flow Reserve
    N Engl J Med 2019 Jun 20;380(25):2418-2428. IF 91.245. 
  • Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson N, Xenou X, Clayton T, Yellon DM. Remote Ischemic Preconditioning and Outcomes in Cardiac Bypass Surgery.
    N Engl J Med 2015 Oct 8;373(15):1408-17. IF 91.245.
  • Bulluck H, Chan MHH, Paradies V, Bryant JA, Hernández-Reséndiz S, Cabrera-Fuentes HA, Watson TJ, Chan MY, Tan JW, Hausenloy DJ. Impact of Cardioprotective Therapies on the Edema-Based Area at Risk by CMR in Reperfused STEMI.
    J Am Coll Cardiol. 2018 Jun 19;71(24):2856-2858. IF 24.094.
  • Madonna R, Van Laake LW, Botker HE, Davidson SM, De Caterina R, Engel FB, Eschenhagen T, Fernandez-Aviles F, Hausenloy DJ, Hulot JS, Lecour S, Leor J, Menasché P, Pesce M, Perrino C, Prunier F, Van Linthout S, Ytrehus K, Zimmermann WH, Ferdinandy P, Sluijter JPG. ESC Working Group on Cellular Biology of the Heart: Tissue Engineering and Cell-Based Therapies for Cardiac Repair in Ischemic Heart Disease and Heart Failure.
    Cardiovasc Res. 2019 Mar 1;115(3):488-500. doi: 10.1093/cvr/cvz010. IF 10.787.
  • Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, Bucciarelli-Ducci C, Croisille P, Dall'Armellina E, Dharmakumar R, Eitel I, Fernández-Jiménez R, Friedrich MG, García-Dorado D, Hausenloy DJ, Kim RJ, Kozerke S, Kramer CM, Salerno M, Sánchez-González J, Sanz J, Fuster V. Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel.
    J Am Coll Cardiol. 2019 Jul 16;74(2):238-256. doi: 10.1016/j.jacc.2019.05.024. IF 24.094.
  • Mei Q, Bansal A, Jayakumar MKG, Zhang Z, Zhang J, Huang H, Yu D, Ramachandra CJA, Hausenloy DJ, Soong TW, Zhang Y. Manipulating energy migration within single lanthanide activator for switchable upconversion emissions towards bidirectional photoactivation.
    Nat Commun. 2019 Sep 27;10(1):4416. doi: 10.1038/s41467-019-12374-4. IF 12.121.
  • Gorog DA, Farag M, Spinthakis N, Yellon DM, Bøtker HE, Kharbanda RK, Hausenloy DJ. Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction- a substudy of the CONDI-2/ERIC-PPCI randomised controlled trial.
    Cardiovasc Res. 2020 Mar 12. pii: cvaa061. doi: 10.1093/cvr/cvaa061. [Epub ahead of print]. IF 10.787.
  • Kompa AR, Greening DW, Kong AM, McMillan PJ, Fang H, Saxena R, Wong RCB, Lees JG, Sivakumaran P, Newcomb AE, Tannous BA, Kos C, Mariana L, Loudovaris T, Hausenloy DJ*, Lim SY*. Sustained subcutaneous delivery of secretome of human cardiac stem cells promotes cardiac repair following myocardial infarction.
    Cardiovasc Res. 2020 Apr 6:cvaa088. doi: 10.1093/cvr/cvaa088. IF 10.787. *Joint Senior
  • Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Pina IL, Rockhold FW, Elghamaz A, Lopez-Sendon JL, Farsky PS, Chernyavskiy AM, Diaz A, Phaneuf D, DeBelder MA, Ma YT, Guzman LA, Khouri M, Sionis A, Hausenloy DJ, Doerr R, Selvanayagam JK, Maggioni AP, Hochman JS, Maron D. Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial.
    Circulation. 2020 Nov 3;142(18):1725-1735. doi: 10.1161/CIRCULATIONAHA.120.050304. IF 23.603.
  • Chan MY, Koh KWL, Poh SC, Marchesseau S, Singh D, Han Y, Ng F, Lim E, Prabath JF, Lee CH, Sim HW, Chen R, Carvalho L, Tan SH, Loh JPY, Tan JWC, Kuwelker K, Amanullah RM, Chin CT, Yip JWL, Lee CY, Gan J, Lo CY, Ho HH, Hausenloy DJ, Tai BC, Richards AM; IMMACULATE Investigators. Remote Postdischarge Treatment of Patients With Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care: The IMMACULATE Randomized Clinical Trial.
    JAMA Cardiol. 2020 Dec 30:e206721. doi: 10.1001/jamacardio.2020.6721. Online ahead of print. If 12.794.
  • Perrino C, Ferdinandy P, Bøtker HE, Brundel BJJM, Collins P, Davidson SM, den Ruijter HM, Engel FB, Gerdts E, Girao H, Gyöngyösi M, Hausenloy DJ, Lecour S, Madonna R, Marber M, Murphy E, Pesce M, Regitz-Zagrosek V, Sluijter JPG, Steffens S, Gollmann-Tepeköylü C, Van Laake LW, Van Linthout S, Schulz R, Ytrehus K. Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart.
    Cardiovasc Res. 2021 Jan 21;117(2):367-385. doi: 10.1093/cvr/cvaa155. IF 10.787.
  • García Del Blanco B, Otaegui I, Rodríguez-Palomares JF, Bayés-Genis A, Fernández-Nofrerías E, Vilalta Del Olmo V, Carrillo X, Ibáñez B, Worner F, Casanova J, Pueo E, González-Juanatey JR, López-Pais J, Bardají A, Bonet G, Fuertes M, Rodríguez-Sinovas A, Ruiz-Meana M, Inserte J, Barba I, Gómez-Talavera S, Martí G, Serra B, Bellera N, Ojeda-Ramos M, Cuellar H, Valente F, Carmona MÁ, Miró-Casas E, Marsal JR, Sambola A, Lidón RM, Bañeras J, Elízaga J, Padilla F, Barrabés JA, Hausenloy DJ, Ferreira-González I, García-Dorado D. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI).
    Basic Res Cardiol. 2021 Jan 25;116(1):4. doi: 10.1007/s00395-021-00842-2. IF 17.165.
  • Kalkhoran S, Kriston-Vizi J, Hernandez-Resendiz S, Crespo-Avilan GE, Rosdah AA, Lees JG, Simoes Da Costa JR, Ling NXY, Holien JK, Samangouei S, Chinda K, Yap EP, Riquelme JA, Ketteler R, Yellon DM, Lim SY, Hausenloy DJ. Hydralazine protects the heart against acute ischemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission.
    Cardiovasc Res. 2021 Jan 2:cvaa343. doi: 10.1093/cvr/cvaa343. Online ahead of print. IF 10.787.
  • Ramachandra CJA, Kp MMJ, Chua J, Hernandez-Resendiz S, Liehn EA, Gan LM, Michaëlsson E, Jonsson MKB, Ryden-Markinhuhta K, Bhat RV, Fritsche-Danielson R, Lin YH, Sadayappan S, Tang HC, Wong P, Shim W, Hausenloy DJ. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Cardiovasc Res. 2021 Mar 10:cvab077. doi: 10.1093/cvr/cvab077. IF 10.787.
  • Ikonomidis I, Vlastos D, Andreadou I, Gazouli M, Efentakis P, Varoudi M, Makavos G, Kapelouzou A, Lekakis J, Parissis J, Katsanos S, Tsilivarakis D, Hausenloy DJ, Alexopoulos D, Cokkinos DV, Bøtker HE, Iliodromitis EK. Vascular conditioning prevents adverse left ventricular remodelling after acute myocardial infarction: a randomised remote conditioning study.
    Bas Res Cardiol. 2021 Feb 6;116(1):9. doi: 10.1007/s00395-021-00851-1. IF 17.165.
  • Figtree GA, Broadfoot K, Casadei B, Califf R, Crea F, Drummond GR, Freedman JE, Guzik TJ, Harrison D, Hausenloy DJ, Hill JA, Januzzi JL, Kingwell BA, Lam CSP, MacRae CA, Misselwitz F, Miura T, Ritchie RH, Tomaszewski M, Wu JC, Xiao J, Zannad F. A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions.
    Eur Heart J. 2021 Apr 14;42(15):1464-1475. doi: 10.1093/eurheartj/ehab068. IF 29.983.
  • Hjortbak MV, Olesen KKW, Seefeldt JM, Lassen TR, Jensen RV, Perkins A, Dodd M, Clayton T, Yellon D, Hausenloy DJ, Bøtker HE; CONDI-2/ERIC-PPCI investigators. Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction.
    Bas Res Cardiol. 2021 May 26;116(1):36. doi: 10.1007/s00395-021-00870-y. IF 17.165.
  • Francis R, Chong J, Ramlall M, Bucciarelli-Ducci C, Clayton T, Dodd M, Engstrøm T, Evans R, Ferreira VM, Fontana M, Greenwood JP, Kharbanda RK, Kim WY, Kotecha T, Lønborg JT, Mathur A, Møller UK, Moon J, Perkins A, Rakhit RD, Yellon DM, Bøtker HE, Bulluck H, Hausenloy DJ. Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy.
    Basic Res Cardiol. 2021 Oct 14;116(1):59. doi: 10.1007/s00395-021-00896-2. IF 17.165.

Research Trials

  • Platelet Inhibition to Target Reperfusion Injury (PITRI trial), funded by NMRC Clinical Trails Grant, Testing whether cangrelor can reduce infarct size and prevent microvascular obstruction (assessed by cardiac MRI) in ST-segment elevation myocardial infarction patients, when compared to placebo.
  • ElectroAcupuncture in CABG surgery (EA-CABG trial), funded by MOH TCMG, Testing whether electroacupuncture can reduce peri-operative myocardial injury in patients undergoing cardiac bypass graft surgery, when compared to placebo.
  • REducing Diabetic macrovascUlar Complications duE to Peripheral Arterial Disease (REDUCE-PAD study), funded by NRF CRP, Testing whether anti-LOX-1Ab can prevent lower limb atheroma plaque inflammation/progression, and improve lower limb microvascular perfusion in diabetic patients with peripheral arterial disease, when compared to control.
  • PASSIvation of Vulnerable plaque with AZD5718 in acuTE coronary syndrome (PASSIVATE trial), funded by CSA (PI Mark Chan) and Astra Zeneca, Testing whether anti-inflammatory 5-lipoxygenase activating protein (FLAP) inhibitor can prevent coronary atheroma progression in patients with recent acute myocardial infarction, when compared to control.
  • Acute Myocardial Infarction: allied Health-Oriented Patient-centered digitally-Enabled care (AMI-HOPE study), funded by MOH HSDP, Testing whether allied-health delivered digitally enabled post-AMI care can improve outcomes in AMI patients.